Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	3.44T
Revenue (ttm)	1.50T
Net Income (ttm)	121.32B
Shares Out	12.68M
EPS (ttm)	9,566.83
PE Ratio	28.38
Forward PE	21.31
Dividend	1,250.00 (0.48%)
Ex-Dividend Date	Dec 27, 2024

Volume	146,126
Average Volume	62,757
Open	262,500
Previous Close	260,000
Day's Range	261,500 - 275,000
52-Week Range	214,500 - 375,000
Beta	0.64
RSI	66.81
Earnings Date	Apr 30, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,330
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.